Key opportunities include capitalizing on rising screen time, increased demand for preservative-free & advanced formulations, ...

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

The FDA announced efforts to make clinical trials more efficient, starting by reviewing data in real time from trials ...

Patients taking Pfizer’s Vyndaqel and Vyndamax for a progressive, often fatal form of heart failure will not see cheaper ...

Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...

New England Journal of Medicine lets Anthony Fauci and his onetime deputy play down results in editorial alongside study from ...

As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...

On March 23, Pfizer issued a press release announcing that a new Lyme disease vaccine candidate has demonstrated “strong ...

Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline developmentCompelling efficacy and tolerability data for zovegalisib ...

Spring is a season of fresh starts – and this year, it’s arriving alongside a wave of health news that touches everything ...